Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Minjuvi tafasitamab Diffuse large B-cell lymphoma (DLBCL) Do not reimburse Complete
Monoferric Iron (III) Isomaltoside 1000 iron deficiency anemia Reimburse with clinical criteria and/or conditions Complete
Monoprost latanoprost glaucoma and ocular hypertension Reimburse with clinical criteria and/or conditions Complete
Movapo apomorphine hydrochloride Parkinson's disease Reimburse with clinical criteria and/or conditions Complete
Mozobil Plerixafor Hematopoietic stem cell mobilizer in non-Hodgkin's lymphoma and multiple myeloma Do not list Complete
Multaq Dronedarone hydrochloride Atrial fibrillation Do not list Complete
Mvasi Bevacizumab mCRC NSCLC Biosimilar N/A Complete
Myalepta metreleptin Leptin deficiency in lipodystrophy Reimburse with clinical criteria and/or conditions Complete
Myfortic Mycophenolate sodium Organ rejection in allogeneic renal transplants, Prophylaxis List in a similar manner to other drugs in class Complete
Myinfla colchicine Atherothrombotic events in coronary artery disease Do not reimburse Complete